CA1155372A - Radioassay process and compositions useful therein - Google Patents
Radioassay process and compositions useful thereinInfo
- Publication number
- CA1155372A CA1155372A CA000367724A CA367724A CA1155372A CA 1155372 A CA1155372 A CA 1155372A CA 000367724 A CA000367724 A CA 000367724A CA 367724 A CA367724 A CA 367724A CA 1155372 A CA1155372 A CA 1155372A
- Authority
- CA
- Canada
- Prior art keywords
- indium
- solution
- animal
- radioactive
- hydroxyquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title abstract description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 27
- 230000002285 radioactive effect Effects 0.000 claims abstract description 24
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims abstract description 13
- 229960003540 oxyquinoline Drugs 0.000 claims abstract description 13
- 239000003960 organic solvent Substances 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 51
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 238000003384 imaging method Methods 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000012857 radioactive material Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 2
- INKYBOIVKCTYGX-UHFFFAOYSA-N indium;quinolin-8-ol Chemical compound [In].C1=CN=C2C(O)=CC=CC2=C1 INKYBOIVKCTYGX-UHFFFAOYSA-N 0.000 claims 4
- 210000000601 blood cell Anatomy 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 17
- 229910052738 indium Inorganic materials 0.000 abstract description 15
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 abstract description 15
- 239000013522 chelant Substances 0.000 abstract description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 26
- 238000000338 in vitro Methods 0.000 description 15
- 238000002372 labelling Methods 0.000 description 15
- 206010000269 abscess Diseases 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 241000283707 Capra Species 0.000 description 10
- 238000009825 accumulation Methods 0.000 description 9
- 230000035508 accumulation Effects 0.000 description 9
- 239000012503 blood component Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 210000001772 blood platelet Anatomy 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 4
- 229940055742 indium-111 Drugs 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- AEGSYIKLTCZUEZ-UHFFFAOYSA-K tri(quinolin-8-yloxy)indigane Chemical compound [In+3].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 AEGSYIKLTCZUEZ-UHFFFAOYSA-K 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- -1 for example Chemical group 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000002471 indium Chemical class 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US108,575 | 1979-12-31 | ||
| US06/108,575 US4348375A (en) | 1979-12-31 | 1979-12-31 | Radioassay process and compositions useful therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1155372A true CA1155372A (en) | 1983-10-18 |
Family
ID=22322962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000367724A Expired CA1155372A (en) | 1979-12-31 | 1980-12-30 | Radioassay process and compositions useful therein |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4348375A (2) |
| JP (2) | JPS56103118A (2) |
| AT (1) | AT368889B (2) |
| BE (1) | BE886930A (2) |
| CA (1) | CA1155372A (2) |
| CH (1) | CH652308A5 (2) |
| DE (1) | DE3049533A1 (2) |
| DK (1) | DK556880A (2) |
| ES (1) | ES8202154A1 (2) |
| FR (1) | FR2474314A1 (2) |
| GB (1) | GB2066664B (2) |
| IT (1) | IT1193721B (2) |
| NL (1) | NL8007094A (2) |
| SE (1) | SE451798B (2) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443426A (en) * | 1982-06-14 | 1984-04-17 | Yale University | Blood agent |
| AU580958B2 (en) * | 1983-07-07 | 1989-02-09 | Mallinckrodt, Inc. | Sterile radioactive indium-containing aqueous solution |
| US4672028A (en) * | 1984-05-23 | 1987-06-09 | Icn Micromedic Systems, Inc. | Compositions and method for simultaneous multiple array of analytes using radioisotope chelate labels |
| US5376356A (en) * | 1989-03-14 | 1994-12-27 | Neorx Corporation | Imaging tissue sites of inflammation |
| US5792444A (en) * | 1989-05-09 | 1998-08-11 | The General Hospital Corporation | Labeled chemotactic peptides to image focal sites of infection or inflammation |
| US5524622A (en) * | 1994-09-20 | 1996-06-11 | Oregon Health Sciences University | Non-invasive method of determining inflammation of the gastrointestinal tract |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017596A (en) * | 1975-03-03 | 1977-04-12 | Research Corporation | Radiopharmaceutical chelates and method of external imaging |
| CA1070695A (en) * | 1975-09-02 | 1980-01-29 | Michael D. Loberg | Iminodiacetic acid pharmaceutical |
| FR2390408A1 (fr) * | 1977-05-11 | 1978-12-08 | Philips France | Procede de marquage par un isotope radioactif d'un sel hydrosoluble d'oxine, ou de ses derives halogenes ou sulfones, produits ainsi marques, procede de marquage des elements figures du sang, et medicaments ainsi obtenus |
| US4335095A (en) * | 1979-03-21 | 1982-06-15 | The Radiochemical Centre Limited | Indium-111 oxine complex composition |
-
1979
- 1979-12-31 US US06/108,575 patent/US4348375A/en not_active Expired - Lifetime
-
1980
- 1980-12-30 CA CA000367724A patent/CA1155372A/en not_active Expired
- 1980-12-30 FR FR8027815A patent/FR2474314A1/fr active Granted
- 1980-12-30 GB GB8041472A patent/GB2066664B/en not_active Expired
- 1980-12-30 AT AT0635880A patent/AT368889B/de not_active IP Right Cessation
- 1980-12-30 DK DK556880A patent/DK556880A/da not_active Application Discontinuation
- 1980-12-30 CH CH9649/80A patent/CH652308A5/de not_active IP Right Cessation
- 1980-12-30 NL NL8007094A patent/NL8007094A/nl not_active Application Discontinuation
- 1980-12-30 IT IT69013/80A patent/IT1193721B/it active
- 1980-12-30 SE SE8009185A patent/SE451798B/sv not_active IP Right Cessation
- 1980-12-30 ES ES498236A patent/ES8202154A1/es not_active Expired
- 1980-12-31 DE DE19803049533 patent/DE3049533A1/de not_active Withdrawn
- 1980-12-31 BE BE0/203373A patent/BE886930A/fr not_active IP Right Cessation
- 1980-12-31 JP JP18946780A patent/JPS56103118A/ja active Pending
-
1989
- 1989-04-04 JP JP1084140A patent/JPH02117623A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES498236A0 (es) | 1982-01-01 |
| CH652308A5 (de) | 1985-11-15 |
| FR2474314B1 (2) | 1984-10-05 |
| GB2066664B (en) | 1984-06-20 |
| FR2474314A1 (fr) | 1981-07-31 |
| JPS56103118A (en) | 1981-08-18 |
| DK556880A (da) | 1981-07-01 |
| SE451798B (sv) | 1987-11-02 |
| AT368889B (de) | 1982-11-25 |
| ES8202154A1 (es) | 1982-01-01 |
| IT8069013A0 (it) | 1980-12-30 |
| DE3049533A1 (de) | 1981-09-17 |
| NL8007094A (nl) | 1981-08-03 |
| ATA635880A (de) | 1982-04-15 |
| BE886930A (fr) | 1981-04-16 |
| US4348375A (en) | 1982-09-07 |
| IT1193721B (it) | 1988-08-24 |
| SE8009185L (sv) | 1981-07-01 |
| GB2066664A (en) | 1981-07-15 |
| JPH02117623A (ja) | 1990-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oite et al. | Quantitative studies of in situ immune complex glomerulonephritis in the rat induced by planted, cationized antigen | |
| Golbus et al. | Experimental glomerulonephritis induced by in situ formation of immune complexes in glomerular capillary wall | |
| US4634586A (en) | Reagent and method for radioimaging leukocytes | |
| Thakur et al. | Preparation and evaluation of 111In-labeled leukocytes as an abscess imaging agent in dogs | |
| JPH08507295A (ja) | 診断造影用のテクネチウム‐９９ｍ標識ペプチド | |
| JPH08502480A (ja) | 放射能標識されたディスインテグリンを使用する血栓検出 | |
| US4917878A (en) | Novel use of a radiolabelled antibody against stage specific embryonic antigen for the detection of occult abscesses in mammals | |
| CA1215372A (en) | Radioactive chelate complexes containing pyridine-n-oxides | |
| Blankenberg et al. | Imaging macrophages and the apoptosis of granulocytes in a rodent model of subacute and chronic abscesses with radiolabeled monocyte chemotactic peptide-1 and annexin V | |
| EiSEN et al. | Noninvasive detection of rejection of transplanted hearts with indium-111-labeled lymphocytes. | |
| CA1155372A (en) | Radioassay process and compositions useful therein | |
| Badimon et al. | New “Ex Vivo” Radioisotopic Method of Quantitation of Platelet Deposition–Studies in Four Animal Species | |
| Thakur et al. | Simplified and efficient labeling of human platelets in plasma using indium-111-2-mercaptopyridine-N-oxide: preparation and evaluation | |
| CA1162330A (en) | In vivo radioassay process | |
| Bergmann et al. | Detection of cardiac transplant rejection with radiolabeled lymphocytes. | |
| Andersen et al. | Inflammatory lesions localized with technetium Tc 99m-labeled leukocytes | |
| Andres et al. | Immunoscintigraphic localization of inflammatory lesions concept, radiolabelling and in vitro testing of a granulocyte specific antibody | |
| Thakur et al. | Evaluation of indium-111-2-mercaptopyridine-N-oxide for labeling leukocytes in plasma: a kit preparation | |
| US5851509A (en) | Radiolabeled glucans covalently linked to a radiolabel binding moiety | |
| Goedemans et al. | Diagnostic compositions containing a chelate of radioactive indium and 8-hydroxyquinoline | |
| Wu et al. | Radioimmunoimaging of experimental arterial and venous thrombi in dogs with 99Tcm-labelled monoclonal anti-activated platelet antibody SZ-51 | |
| US4705678A (en) | Sterile radioactive indium-containing aqueous solution | |
| Issekutz et al. | [25] Cellular and vascular phenomena in inflammation | |
| JPS6229533A (ja) | 放射線分析用放射性金属化合物含有組成物 | |
| Thakur | The radioactive compounds of gallium and indium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry | ||
| MKEX | Expiry |
Effective date: 20001018 |